Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-grass pollen mixture extract is an allergenic extract immunotherapy used for the diagnosis and treatment of grass pollen-induced allergic rhinitis, with or without conjunctivitis. It is composed of extracts from six different types of grass pollen: Agrostis gigantea (Redtop), Dactylis glomerata (Orchard grass), Festuca pratensis (Meadow Fescue), Lolium perenne (Perennial Rye), Phleum pratense (Timothy), and Poa pratensis (Kentucky Bluegrass). The therapy works by repeatedly exposing the immune system to these specific allergens to induce immunological tolerance, thereby reducing the allergic response upon natural exposure. Various formulations have been developed by companies like ALK-Abello and Allergopharma, including subcutaneous injections and sublingual liquid solutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-grass pollen mixture extract.